Next-Generation Immunotherapies Market Size, Share, Industry Trends and Forecast, 2026–2035

Next-Generation Immunotherapies Market Overview

The global Next-Generation Immunotherapies Market reached USD 130.41 billion in 2025 and is expected to reach USD 261.49 billion by 2035, growing at a CAGR of 7.2% during the forecast period 2026–2035.

The market is projected to add approximately USD 131.08 billion in value between 2025 and 2035, reflecting the growing role of immune-directed treatments across hematological malignancies and solid tumors. Expansion is being supported by advances in engineered cellular therapies, immune-cell engagers, biomarker-selected treatments, therapeutic cancer vaccines and manufacturing technologies capable of producing increasingly complex, patient-specific medicines.

Next-generation immunotherapies are advanced treatments designed to redirect, amplify, engineer or regulate the immune system with greater precision than conventional immunotherapy. The market includes CAR-T-cell therapies, T-cell receptor-engineered therapies, tumor-infiltrating lymphocyte therapies, CAR-NK platforms, bispecific and multispecific immune-cell engagers, therapeutic cancer vaccines, oncolytic viruses, engineered cytokines and next-generation immune-checkpoint systems.

The commercial market remains concentrated in hematological cancers, where CD19- and BCMA-directed therapies have established recognizable clinical, regulatory and manufacturing pathways. However, future competitive differentiation is increasingly connected to solid-tumor efficacy, faster manufacturing, lower toxicity, off-the-shelf availability and the ability to administer advanced treatments across a broader network of qualified cancer centers.

The market is also moving beyond the first generation of patient-specific CAR-T products. Developers are evaluating donor-derived cellular therapies, in-vivo immune-cell programming, multi-antigen receptors, logic-gated cells, armored T cells, tumor-selective cytokines and automated manufacturing systems.

These developments are gradually changing the market from a collection of specialized experimental therapies into a broader oncology platform encompassing product development, companion diagnostics, manufacturing, logistics, treatment-center qualification and long-term patient monitoring.

Next-Generation Immunotherapies Market Size and Forecast

Chart title: Global Next-Generation Immunotherapies Market Size, 2025–2035

• Market size in 2025: USD 130.41 billion
• Forecast market size in 2035: USD 261.49 billion
• Absolute market expansion: USD 131.08 billion
• CAGR during 2026–2035: 7.2%
• Base year: 2025
• Historical period: 2023–2024
• Forecast period: 2026–2035
• Available data period: 2023–2035

The market is expected to approximately double over the forecast period. This expansion will not be driven by a single product class. Growth will be distributed across commercial CAR-T therapies, T-cell engagers, therapeutic vaccines, engineered cytokines, solid-tumor cell therapies and manufacturing platforms designed to improve treatment availability.

Revenue growth will also depend on the movement of advanced immunotherapies into earlier treatment lines. Products initially approved for heavily pretreated patients are increasingly being evaluated in populations with fewer previous therapies, potentially expanding the eligible patient base.

Key Takeaways

• The global next-generation immunotherapies market was valued at USD 130.41 billion in 2025.
• The market is projected to reach USD 261.49 billion by 2035.
• Market revenue is expected to increase at a CAGR of 7.2% from 2026 to 2035.
• Engineered cellular immunotherapies remain a central value pool within the market, supported by approved CAR-T, TCR-T and TIL products.
• Autologous therapies currently have the most established clinical and commercial position, while allogeneic and in-vivo platforms are being developed to shorten manufacturing timelines and improve treatment availability.
• Hematological malignancies continue to represent the strongest commercial application because of validated targets such as CD19 and BCMA.
• Solid tumors represent the most important long-term development opportunity, particularly for therapies targeting Claudin18.2, GD2, B7-H3, GPC3, HER2, mesothelin, MAGE-A4 and personalized neoantigens.
• Satricabtagene autoleucel became the first CAR-T-cell therapy approved specifically for a solid-tumor indication in June 2026, establishing an important regulatory and commercial precedent for solid-tumor cellular immunotherapy.
• Cytokine release syndrome, neurotoxicity, prolonged cytopenia and on-target off-tumor effects remain important safety considerations.
• Automated, closed and digitally controlled manufacturing is emerging as a strategic requirement for expanding production capacity and improving batch consistency.
• The United States has the most mature commercial and clinical-development ecosystem, while Japan, Europe, China and Australia are expanding regulatory pathways, clinical-trial infrastructure and advanced-therapy manufacturing capabilities.

Next Generation Immunotherapies Market Scope

2026 Developments Transforming the Next-Generation Immunotherapies Market

First CAR-T Approval Specifically for a Solid Tumor

In June 2026, China’s National Medical Products Administration approved CARsgen Therapeutics’ satricabtagene autoleucel, or satri-cel, for eligible patients with Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma following at least two previous lines of treatment.

Satri-cel is an autologous CAR-T-cell therapy targeting Claudin18.2. Its approval established the first regulatory precedent for a CAR-T product specifically approved for a solid-tumor indication. The milestone is commercially significant because solid tumors have historically been more difficult to address with cellular therapies than hematological cancers.

The approval is expected to strengthen development interest in Claudin18.2 and other solid-tumor targets. It may also encourage investment in technologies designed to improve immune-cell trafficking, persistence, and activity within immunosuppressive tumor environments.

New Funding Focuses on Solid-Tumor Cell and Gene Therapy

The Alliance for Cancer Gene Therapy opened its 2026 Investigator Award for cell and gene therapy research in solid tumors. The funding program supports translational projects involving CAR-T, TCR-T, TIL, CAR-NK, gene-edited cellular therapies and other immune-engineering approaches.

The program reflects the growing research focus on antigen heterogeneity, limited immune-cell infiltration, treatment resistance and the need for controllable safety mechanisms in solid tumors.

T-Cell Engagers Move into Earlier Treatment Settings

On March 5, 2026, the US Food and Drug Administration approved teclistamab in combination with daratumumab hyaluronidase for adults with relapsed or refractory multiple myeloma who had received at least one previous line of therapy.

The approval expanded the addressable population for an off-the-shelf BCMA-directed CD3 T-cell engager. It also demonstrated how immune-cell engagers can compete and coexist with CAR-T therapies across different treatment lines, clinical settings and patient populations.

Cytokine-Safety Management Remains a Development Priority

As highly active immune therapies move into broader patient populations, developers are increasingly evaluating preventive and early-intervention strategies for cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome.

Current approaches include IL-6 pathway inhibition, IL-1 pathway modulation, dose optimization, step-up dosing, conditional immune activation and built-in cellular safety switches. Safety improvements could reduce hospitalization requirements, support outpatient administration and enable more cancer centers to provide complex immunotherapies.

Automated Manufacturing Advances Toward Clinical Deployment

In February 2026, Cellares and the University of Wisconsin School of Medicine and Public Health expanded their partnership to support clinical manufacturing and regulatory development of a CRISPR-edited GD2 CAR-T investigational therapy for pediatric and adult solid tumors.

The collaboration is designed to advance automated clinical production and support an investigational new drug submission. It illustrates how academic cell-therapy programs are increasingly partnering with specialized manufacturing platforms to improve reproducibility, regulatory readiness and commercial scalability.

Cell-Therapy Manufacturing Attracts Major Investment

Johnson & Johnson announced an investment of more than USD 1 billion in a next-generation cell-therapy manufacturing facility in Montgomery County, Pennsylvania. The facility is intended to expand US manufacturing capacity for advanced medicines and strengthen the company’s long-term cell-therapy infrastructure.

Cellares raised USD 257 million in January 2026 to accelerate the industrialization of automated cell-therapy manufacturing. The company is developing manufacturing capacity across the United States, Europe and Japan and has agreements supporting commercial-scale production for multiple cell-therapy programs.

These investments demonstrate that manufacturing capacity is becoming a competitive asset rather than a back-end operational function. Companies capable of reducing production time, labor dependence, batch failures and geographic delivery constraints may gain a significant commercial advantage.

Next-Generation Immunotherapies Market Scope and Definition

For this report, next-generation immunotherapies are defined as advanced therapeutic platforms that actively engineer, redirect, amplify or regulate immune responses against cancer.

Included in the Market

• CAR-T-cell therapies
• TCR-engineered T-cell therapies
• Tumor-infiltrating lymphocyte therapies
• CAR-NK and engineered natural killer-cell platforms
• Autologous cellular immunotherapies
• Allogeneic cellular immunotherapies
• In-vivo immune-cell engineering
• Bispecific and multispecific immune-cell engagers
• Personalized neoantigen vaccines
• Therapeutic cancer vaccines
• Oncolytic virus immunotherapies
• Engineered cytokines
• Immunocytokines
• Next-generation checkpoint inhibitors
• Immune co-stimulatory agonists
• Logic-gated cellular therapies
• Armored and gene-edited immune-cell therapies
• Combination platforms in which immune activation is the principal therapeutic mechanism

Excluded from the Market

• Conventional monoclonal antibodies without an advanced immune-engaging mechanism
• Preventive infectious-disease vaccines
• COVID-19 vaccines and treatments
• Traditional chemotherapy
• Conventional radiotherapy
• Standard hematopoietic stem-cell transplantation
• Supportive immune-modulating medicines
• Antibody-drug conjugates whose principal mechanism is cytotoxic payload delivery
• General immunosuppressive treatments

This market definition prevents the inclusion of mature oncology therapies that do not represent next-generation immune engineering or immune-redirection technologies.

Next-Generation Immunotherapies Market Dynamics

Expanding Clinical Validation of Engineered Immune Therapies

The approval of multiple CAR-T-cell products, the first TCR-engineered therapy and a commercial TIL therapy has established recognizable regulatory pathways for advanced cellular immunotherapies.

The FDA maintains a growing list of licensed cellular and gene therapy products, reflecting the transition of several platforms from experimental development into regulated clinical use.

These approvals have helped define expectations for clinical endpoints, manufacturing controls, product release testing, long-term follow-up, treatment-center qualification and post-market safety monitoring.

Developers entering the market can therefore design programs around a more established regulatory foundation than was available during the earliest stage of CAR-T development.

Solid Tumors Represent the Largest Untapped Opportunity

Cellular immunotherapies have achieved their strongest results in hematological malignancies, where target antigens are comparatively well defined and therapeutic cells can reach malignant cells more directly.

Solid tumors present more complex biological barriers, including:

• Antigen heterogeneity
• Limited immune-cell trafficking
• Dense tumor stroma
• Immunosuppressive microenvironments
• Reduced cell persistence
• On-target off-tumor toxicity
• Antigen loss and escape
• Variable target expression

Developers are addressing these barriers through dual- and multi-antigen targeting, regional administration, armored cells, checkpoint-resistant designs, cytokine secretion, stromal targeting and inducible safety controls.

The approval of satri-cel provides evidence that appropriately selected solid-tumor targets can support regulatory and commercial development. It may increase investment in gastric, pancreatic, brain, liver, lung, ovarian and pediatric solid-tumor programs.

Bispecific and Multispecific Therapies Expand Off-the-Shelf Access

Bispecific immune-cell engagers connect an immune cell to a cancer-associated target without requiring patient-specific cell collection and manufacturing.

Their immediate availability creates a different treatment and commercial model from autologous cellular therapy. These products may be administered across a broader hospital network, provided that treatment centers can manage cytokine release syndrome, infection risks and other immune-related complications.

Competition between immune-cell engagers and cellular therapies will increasingly depend on:

• Response depth
• Response durability
• Treatment frequency
• Safety
• Hospitalization requirements
• Manufacturing time
• Total treatment cost
• Ability to move into earlier treatment lines
• Availability of subsequent treatment options

The 2026 FDA approval of teclistamab with daratumumab in an earlier relapsed or refractory multiple myeloma setting demonstrates the expanding commercial relevance of T-cell engagers.

Precision Biomarkers Become Essential to Commercialization

Next-generation immunotherapies increasingly require precise patient-selection systems. Eligibility may depend on:

• Tumor-antigen expression
• HLA subtype
• Target density
• Genomic alterations
• Immune-cell composition
• Previous treatments
• Tumor microenvironment characteristics
• Neoantigen profile

TCR-T products may require both a specific antigen and a compatible HLA type. Personalized cancer vaccines may require tumor sequencing, computational neoantigen prediction and patient-specific manufacturing.

As treatments become more targeted, companion diagnostics and biomarker-based patient identification will become integral to clinical development, treatment-center activation and commercial adoption.

Manufacturing Complexity Restrains Wider Adoption

Autologous cell therapies require the collection, transportation, modification, expansion, testing and reinfusion of cells obtained from an individual patient.

This process can be difficult to scale because of:

• Variable patient starting material
• Complex chain-of-identity requirements
• Limited manufacturing slots
• Lengthy quality-control processes
• Cryogenic transportation
• High skilled-labor requirements
• Batch failure risk
• Differences between clinical and commercial processes
• Limited treatment-center coverage
• Long vein-to-vein timelines

Product-specific manufacturing timelines demonstrate the operational complexity of patient-specific therapies. Iovance states that Amtagvi manufacturing may take approximately 34 days from receipt of tumor tissue until the product is available for shipment, while Autolus highlights a 20-day vein-to-release process for Aucatzyl and is working toward a shorter target.

Automation, closed processing, standardized release testing and distributed manufacturing are therefore becoming important sources of competitive differentiation.

Safety Engineering Becomes a Core Product Feature

Cytokine release syndrome, neurotoxicity, prolonged cytopenia, serious infection, immune-mediated organ damage and on-target off-tumor toxicity can limit the therapeutic window of highly active immunotherapies.

The industry is responding through:

• Suicide switches
• Elimination genes
• Logic-gated antigen recognition
• Tunable receptor activity
• Conditional immune activation
• Local or regional administration
• Masked cytokines
• Lower-affinity receptor designs
• Step-up dosing
• Prophylactic toxicity management
• Real-time biomarker monitoring

Safety engineering is increasingly becoming part of the initial product architecture rather than a risk-management measure added late in development.

Next-Generation Immunotherapies Market Segmentation Analysis

By Modality

The market is segmented into:

• Engineered cellular immunotherapies
• Bispecific and multispecific immune-cell engagers
• Therapeutic cancer vaccines
• Oncolytic virus immunotherapies
• Engineered cytokines and immunocytokines
• Next-generation checkpoint and immune-agonist therapies
• Other immune-programming platforms

Engineered Cellular Immunotherapies

Engineered cellular immunotherapies form one of the most commercially and scientifically advanced segments of the market.

The category includes:

• CAR-T
• TCR-T
• TIL
• CAR-NK
• Gene-edited immune cells
• Logic-gated cells
• Armored cellular therapies

CAR-T therapies have the strongest commercial foundation, particularly in B-cell malignancies and multiple myeloma. TCR-T and TIL platforms are extending engineered cellular therapy into solid tumors by recognizing intracellular antigens or expanding naturally occurring tumor-reactive lymphocytes.

The FDA’s approved cellular and gene therapy portfolio includes multiple CAR-T products as well as TCR-T and TIL therapies, demonstrating the widening regulatory diversity of the segment.

Bispecific and Multispecific Immune-Cell Engagers

This segment includes antibodies and related proteins designed to bind a tumor-associated antigen and an immune-cell receptor simultaneously.

The segment benefits from off-the-shelf availability and avoids individualized cell manufacturing. Its future growth will depend on improved administration schedules, reduced immune toxicity, movement into earlier treatment lines and development of effective solid-tumor targets.

Therapeutic Cancer Vaccines

Therapeutic cancer vaccines stimulate immune responses against an existing tumor rather than preventing infectious disease.

Personalized neoantigen vaccines use tumor sequencing and computational target selection to identify patient-specific antigens. Progress in mRNA delivery, genomic profiling and artificial intelligence-assisted antigen prediction is supporting the development of more individualized vaccine platforms.

Oncolytic Virus Immunotherapies

Oncolytic viruses are designed to infect and destroy tumor cells while stimulating local and systemic immune activity.

Next-generation products are being engineered to deliver cytokines, immune-cell engagers or checkpoint-modulating proteins directly into the tumor microenvironment. Their potential role is especially relevant in solid tumors that respond poorly to systemic immune activation alone.

Engineered Cytokines and Immunocytokines

Engineered cytokines are intended to preserve immune-stimulating activity while reducing systemic toxicity.

Development strategies include:

• Masked cytokines
• Tumor-targeted cytokines
• Conditionally active proteins
• Cytokine-antibody fusions
• Cytokines delivered by engineered cells
• Cytokines delivered through oncolytic viruses

Advanced Checkpoint and Immune-Agonist Platforms

This segment includes bispecific checkpoint inhibitors, co-stimulatory receptor agonists and therapies designed to overcome resistance or immune exhaustion.

Future development will be influenced by the ability to identify biomarker-defined patient populations and create combinations that improve efficacy without causing unacceptable immune toxicity.

By Cell Source

The market is segmented into:

• Autologous
• Allogeneic
• In-vivo engineered

Autologous Therapies

Autologous therapies use cells collected from the individual patient. They currently have the most established position across commercial CAR-T, TCR-T and TIL products.

Their advantages include:

• Lower graft-versus-host risk
• Established regulatory precedents
• Patient-specific product identity
• Demonstrated clinical activity in selected cancers

Their limitations include individualized manufacturing, variable starting material, complex logistics and long treatment timelines.

Allogeneic Therapies

Allogeneic therapies use cells obtained from healthy donors or standardized cell banks.

They are being developed as ready-to-use products that could:

• Reduce waiting time
• Enable larger manufacturing batches
• Support repeat dosing
• Lower production costs
• Increase product availability

Gene editing is frequently used to reduce graft-versus-host disease and host immune rejection. Commercial success will depend on persistence, safety, potency and consistent manufacturing.

In-Vivo Engineered Therapies

In-vivo platforms deliver genetic instructions directly into a patient to reprogram immune cells inside the body.

These treatments could eliminate leukapheresis and ex-vivo cell manufacturing. However, developers must demonstrate precise cell targeting, acceptable off-target activity, controllable gene expression and durable therapeutic effects.

By Therapeutic Target

The market is segmented into:

• CD19
• BCMA
• Claudin18.2
• GD2
• B7-H3
• GPC3
• HER2
• Mesothelin
• EGFR and EGFRvIII
• NY-ESO-1
• MAGE-A4
• PRAME
• Personalized neoantigens
• Other tumor-associated targets

CD19 and BCMA have the most established position in approved cellular immunotherapies. Solid-tumor development is increasingly distributed across cell-surface antigens, intracellular cancer-testis antigens and patient-specific neoantigens.

Claudin18.2 gained particular commercial relevance following the 2026 approval of satri-cel for eligible patients with advanced gastric or gastroesophageal junction cancer.

By Cancer Type

The market is segmented into:

• Hematological malignancies
• Solid tumors

Hematological Malignancies

Hematological malignancies currently represent the most mature commercial application.

Major indications include:

• Acute lymphoblastic leukemia
• Diffuse large B-cell lymphoma
• Mantle cell lymphoma
• Follicular lymphoma
• Multiple myeloma
• Other B-cell malignancies

These cancers benefit from validated targets, established treatment-center networks and increasing evaluation of advanced immunotherapies in earlier treatment settings.

Solid Tumors

Solid tumors represent the largest long-term pipeline-expansion opportunity.

Priority indications include:

• Gastric cancer
• Gastroesophageal junction cancer
• Melanoma
• Synovial sarcoma
• Glioblastoma
• Neuroblastoma
• Pancreatic cancer
• Liver cancer
• Lung cancer
• Ovarian cancer
• Breast cancer
• Prostate cancer
• Colorectal cancer
• Other pediatric and adult solid tumors

Commercial progress will depend on target selection, tumor penetration, immune-cell persistence, safety and the ability to prevent antigen escape.

By Development Stage

The market is segmented into:

• Discovery and preclinical
• Phase I
• Phase I/II
• Phase II
• Phase III
• Regulatory review
• Commercialized

The discovery and early clinical pipeline remains broad because new platforms must establish target selectivity, persistence, safety and manufacturing feasibility.

Commercial revenue is concentrated in approved products, while licensing and partnership activity frequently occurs during preclinical or early clinical development.

By Route of Administration

The market is segmented into:

• Intravenous
• Subcutaneous
• Intratumoral
• Intracavitary
• Intramuscular
• Other regional administration routes

Intravenous administration remains the primary route for systemic cellular immunotherapies.

Subcutaneous administration is becoming increasingly relevant for selected immune-cell engagers. Intratumoral and regional administration are being explored for solid tumors to improve local activity and reduce systemic exposure.

By Manufacturing Model

The market is segmented into:

• Centralized in-house manufacturing
• Centralized contract manufacturing
• Integrated automated manufacturing
• Point-of-care manufacturing
• Decentralized manufacturing
• Distributed regional manufacturing
• In-vivo immune-cell engineering

Centralized in-house manufacturing remains important for companies seeking direct control over product quality, intellectual property and supply.

Contract manufacturing allows smaller developers to access specialized infrastructure without building full internal production capabilities.

Automated and distributed models are expected to gain importance as patient volumes increase and companies expand across multiple geographic markets. Cellares’ manufacturing network and its partnerships illustrate the industry’s movement toward standardized, automated and geographically distributed production.

By End User

The market is segmented into:

• Hospitals
• Comprehensive cancer centers
• Authorized cell-therapy treatment centers
• Specialty oncology clinics
• Academic and research institutions
• Contract development and manufacturing organizations
• Biotechnology and pharmaceutical companies

Comprehensive cancer centers and authorized treatment centers currently account for a substantial share of advanced cellular therapy administration because they can provide leukapheresis, lymphodepletion, intensive monitoring and management of severe immune-related toxicities.

Broader adoption will depend on whether next-generation products can reduce hospitalization, simplify toxicity management and operate through less complex treatment-center networks.

Regional Analysis

North America

North America is expected to retain a leading position in the next-generation immunotherapies market through 2035.

The United States combines:

• A large clinical-trial network
• Multiple approved cellular therapies
• Established cancer centers
• Specialized manufacturing infrastructure
• Strong biotechnology investment
• Extensive academic research
• A developed regulatory pathway

The FDA’s licensed product portfolio includes multiple CAR-T therapies and approved TCR-T and TIL products, demonstrating the breadth of the US advanced immunotherapy ecosystem.

Manufacturing investment is also accelerating. Johnson & Johnson’s planned Pennsylvania facility and Cellares’ automated manufacturing expansion illustrate the increasing strategic importance of domestic production capacity.

Regional growth will be influenced by solid-tumor CAR-T development, in-vivo engineering, personalized cancer vaccines, bispecific antibodies and automated manufacturing.

However, reimbursement complexity, geographic concentration of treatment centers and high treatment-delivery costs may continue to restrict access.

Europe

Europe has an established centralized regulatory pathway for advanced therapy medicinal products, supported by national-level pricing and reimbursement systems.

Regional strengths include:

• University hospital networks
• Cell and gene therapy research
• Multinational clinical trials
• Contract manufacturing capabilities
• Strong regulatory oversight
• Established oncology centers

Germany represents one of Europe’s most important markets because of its hospital infrastructure, clinical-research capabilities and formal health-technology assessment environment.

European adoption will depend on:

• Evidence accepted by national reimbursement authorities
• Long-term survival data
• Quality-of-life outcomes
• Manufacturing reliability
• Cross-border logistics
• Qualified treatment-center capacity
• Real-world evidence

Automated manufacturing investment is also expanding. Cellares announced a European manufacturing site in Leiden, Netherlands, to support commercial-scale cell-therapy production for European patient populations.

Asia-Pacific

Asia-Pacific is expected to record substantial market expansion as China, Japan, South Korea and Australia strengthen advanced-therapy development.

China’s approval of the first CAR-T therapy specifically for a solid-tumor indication has increased the region’s importance within the global cellular immunotherapy landscape.

The regional opportunity is supported by:

• Large cancer patient populations
• Expanding clinical-trial activity
• Domestic biotechnology companies
• Government support for advanced therapies
• Improving manufacturing capacity
• Growing precision-oncology infrastructure

Japan

Japan has a dedicated regulatory framework for regenerative medical products and offers conditional and time-limited approval mechanisms under defined circumstances.

PMDA materials describe pathways intended to support timely access while requiring continued evidence generation and post-market evaluation.

Future market development in Japan will depend on:

• Expansion of qualified treatment centers
• National Health Insurance reimbursement
• Domestic manufacturing
• Clinical-trial recruitment
• Shorter patient-to-manufacturing logistics
• Alignment between Japanese and global development programs

Cellares is developing manufacturing capacity in Kashiwa City, reinforcing Japan’s potential role as a regional cell-therapy production center.

Australia

Australia has a strong early-phase clinical-trial environment, specialist cancer research institutions and growing advanced-therapy manufacturing capabilities.

Its opportunity lies in connecting academic research, translational funding and multinational clinical-development programs. Expansion will depend on reimbursement, treatment-center capacity and domestic manufacturing that can reduce reliance on long-distance international logistics.

South America

South America remains an emerging market for next-generation immunotherapies.

Brazil is expected to represent an important regional opportunity because of its population size, cancer burden and established oncology centers. However, high treatment costs, limited manufacturing infrastructure and uneven access to advanced cancer care may restrain adoption.

Partnerships involving international developers, local hospitals and regional manufacturing organizations will be important for future growth.

Middle East and Africa

The Middle East and Africa market remains at an early stage of development.

Growth is expected to be concentrated in countries investing in specialist oncology centers, precision medicine and advanced hospital infrastructure.

Access remains limited by:

• High therapy costs
• Limited treatment-center availability
• Shortage of specialized personnel
• Manufacturing and logistics constraints
• Uneven reimbursement

The initial opportunity is likely to focus on selected referral centers and cross-border treatment partnerships.

Competitive Landscape

Competition is shifting from ownership of individual therapeutic assets toward control of integrated platforms covering target discovery, cell engineering, clinical development, companion diagnostics, manufacturing and treatment delivery.

Johnson & Johnson and Legend Biotech

Johnson & Johnson and Legend Biotech have established a significant position in BCMA-directed cellular therapy through Carvykti.

Their competitive strategy includes:

• Expanding patient access
• Increasing manufacturing capacity
• Advancing additional cell-therapy programs
• Supporting commercial supply across major markets

Legend Biotech is expanding its US and European manufacturing presence through its collaboration with Johnson & Johnson, while Johnson & Johnson is investing more than USD 1 billion in a new Pennsylvania cell-therapy facility.

Bristol Myers Squibb

Bristol Myers Squibb participates in the market through approved CAR-T therapies, including Abecma and Breyanzi.

Its competitive position is supported by commercial cell-therapy experience, treatment-center relationships and global manufacturing partnerships. Bristol Myers Squibb has also reserved automated manufacturing capacity with Cellares in the United States, Europe and Japan.

Gilead Sciences and Kite

Kite, a Gilead company, has an established CAR-T portfolio through Yescarta and Tecartus.

The company’s dedicated cellular-therapy infrastructure and experience with authorized treatment centers provide an important advantage as CAR-T therapies move into broader patient populations and earlier treatment lines.

Tecartus remains approved for eligible adults with relapsed or refractory mantle cell lymphoma and B-cell precursor acute lymphoblastic leukemia.

Novartis

Novartis established one of the earliest commercial CAR-T positions through Kymriah.

Its experience in global cell and gene therapy development provides a foundation for manufacturing partnerships, geographic commercialization and future advanced-therapy programs.

Iovance Biotherapeutics

Iovance is a leading participant in tumor-infiltrating lymphocyte therapy.

Amtagvi is an autologous, tumor-derived T-cell therapy. The treatment is produced from lymphocytes collected from an individual patient’s tumor and expanded at a specialized manufacturing facility.

Iovance operates a 136,000-square-foot cell-therapy manufacturing center in Philadelphia and is studying TIL therapies in additional solid tumors.

Adaptimmune and US WorldMeds

Tecelra established an important regulatory precedent as the first FDA-approved engineered TCR therapy.

The product is intended for eligible adults with unresectable or metastatic synovial sarcoma whose tumors express MAGE-A4 and who have qualifying HLA types. Its commercialization model highlights the importance of biomarker testing, authorized treatment centers and patient-specific manufacturing.

Autolus Therapeutics

Autolus develops programmable CAR-T-cell therapies and maintains proprietary viral-vector and semi-automated manufacturing capabilities.

Aucatzyl is indicated for eligible adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The product is manufactured at the company’s Nucleus facility in Stevenage, United Kingdom.

CARsgen Therapeutics

CARsgen develops autologous and allogeneic CAR-T products for hematological malignancies and solid tumors.

Satri-cel targets Claudin18.2 and was approved in China in June 2026 for eligible patients with advanced gastric or gastroesophageal junction adenocarcinoma. The approval gives CARsgen a differentiated position in solid-tumor CAR-T development.

Cellares

Cellares operates an integrated development and manufacturing model focused on automated cell-therapy production.

Its competitive position is based on:

• Automated manufacturing
• Integrated quality control
• Digital process architecture
• Global manufacturing sites
• Commercial-scale capacity agreements
• Support for CAR-T, TCR-T and other cellular modalities

The company’s 2026 partnerships and financing demonstrate growing demand for manufacturing systems capable of supporting advanced therapies at commercial scale.

Key Players in the Next-Generation Immunotherapies Market

CAR-T and Engineered Cellular Therapy Companies

• Johnson & Johnson
• Legend Biotech
• Bristol Myers Squibb
• Gilead Sciences
• Kite Pharma
• Novartis
• Autolus Therapeutics
• CARsgen Therapeutics
• Allogene Therapeutics
• Cellectis
• CRISPR Therapeutics
• Caribou Biosciences

TCR-T and T-Cell Platform Companies

• Adaptimmune
• Immunocore
• Immatics
• TScan Therapeutics
• BioNTech
• Medigene

TIL Therapy Companies

• Iovance Biotherapeutics
• Instil Bio
• Achilles Therapeutics
• Turnstone Biologics

CAR-NK and Natural Killer-Cell Companies

• Fate Therapeutics
• Nkarta
• Artiva Biotherapeutics
• Century Therapeutics

Bispecific and Multispecific Immunotherapy Companies

• Johnson & Johnson
• Amgen
• Roche
• Genmab
• Regeneron Pharmaceuticals
• AbbVie
• Pfizer

Therapeutic Vaccine and Personalized Immunotherapy Companies

• BioNTech
• Moderna
• Merck
• Gritstone Bio
• Nouscom
• Transgene

Oncolytic Immunotherapy Companies

• Replimune
• Amgen
• Genelux
• Oncorus
• Transgene

Engineered Cytokine Companies

• Synthekine
• Werewolf Therapeutics
• Xilio Therapeutics
• Philogen
• Nektar Therapeutics

Cell-Therapy Manufacturing and Technology Companies

• Cellares
• Lonza
• Catalent
• Thermo Fisher Scientific
• Charles River Laboratories
• WuXi Advanced Therapies
• Minaris Regenerative Medicine
• Miltenyi Biotec

Companies should be compared according to modality, therapeutic target, clinical stage, manufacturing model, approved indication, treatment-center network and geographic development rights rather than being presented as one undifferentiated competitor list.

Key Developments

• July 2026 – Bristol Myers Squibb Received FDA Approval for Opdivo Qvantig - The U.S. FDA approved Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy), a subcutaneous formulation of nivolumab for multiple solid tumors. The approval offers a faster administration option compared with intravenous infusion and expands patient access to immune checkpoint inhibitor therapy.
• June 2026 – BioNTech Acquired CureVac - BioNTech completed its acquisition of CureVac, strengthening its mRNA research capabilities and expanding its next-generation immunotherapy pipeline across oncology and infectious diseases. The transaction is expected to accelerate development of personalized cancer immunotherapies.
• May 2026 – Gilead Sciences Reported Positive Trodelvy Combination Data - Gilead Sciences announced encouraging clinical results evaluating Trodelvy® in combination with immune checkpoint inhibitors, demonstrating improved anti-tumor activity in multiple solid tumor indications and reinforcing combination immunotherapy strategies.
• March 2026 – AstraZeneca Expanded T-cell Engager Clinical Programs - AstraZeneca advanced multiple T-cell engager candidates into late-stage clinical development, strengthening its oncology immunotherapy portfolio focused on hematologic malignancies and solid tumors.
• January 2026 – Roche Expanded Personalized Cancer Immunotherapy Research - Roche announced additional investments in personalized immunotherapy platforms integrating biomarker-guided treatment selection, AI-enabled drug discovery, and combination immunotherapy development to improve patient outcomes.

Why Purchase the Report?

• To visualize the global next generation immunotherapies market segmentation based on immunotherapy type, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of next generation immunotherapies market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global next generation immunotherapies market report would provide approximately 61 tables, 59 figures and 267 Pages.

Target Audience

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies